Bromocriptine value in the treatment of patients with peripartum cardiomyopathy

Mirzarakhimova Saodat Timurovna; Abdullaev Timur Atanazarovich; Tsoy Igor Arsenievich; Nizamov Ulugbek Irgashevich

doi:10.33545/26634104.2020.v2.i2a.26

Bromocriptine value in the treatment of patients with peripartum cardiomyopathy

Author(s):

Mirzarakhimova Saodat Timurovna, Abdullaev Timur Atanazarovich, Tsoy Igor Arsenievich, Nizamov Ulugbek Irgashevich

Abstract:

A peripartum cardiomyopathy is a relatively rare heart disease that affects women in the third trimester of pregnancy and/or after giving birth, characterized by high variability of the course and prognosis with the potential for full restoration of left ventricular function. The pathophysiological mechanism in this disease is associated with prolactin degradation disorder, and therefore, the medications that suppress lactation have promising clinical significance.

DOI: 10.33545/26634104.2020.v2.i2a.26

Pages: 13-16 | 869 Views 263 Downloads

Download (480KB)

How to cite this article:

Mirzarakhimova Saodat Timurovna, Abdullaev Timur Atanazarovich, Tsoy Igor Arsenievich, Nizamov Ulugbek Irgashevich. Bromocriptine value in the treatment of patients with peripartum cardiomyopathy. Int. J. Cardiol. Res. 2020;2(2):13-16. DOI: 10.33545/26634104.2020.v2.i2a.26

Vol. 2, Issue 2, Part A (2020)

Bromocriptine value in the treatment of patients with peripartum cardiomyopathy

Related Links

Related Journal Subscription